Browse drugs by:

Fast Track Designation for Enobosarm for Muscle Wasting in NSCLC

GTx, Inc. announced that the FDA has designated enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC) as a Fast Track development program.